G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 7, 2000, Pages 1789-1795

  Pihlajamäki, Jussi ^a   Karjalainen, Leena ^a   Karhapää, Pauli ^a   Vauhkonen, Ilkka ^a   Taskinen, Marja Riitta ^b   Deeb, Samir S ^c   Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Familial combined hyperlipidemia; Hepatic lipase; Hypertriglyceridemia; Insulin resistance

Indexed keywords

GLUCOSE; INSULIN; LIVER TRIACYLGLYCEROL LIPASE; NEUTRAL INSULIN;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; ENZYME ACTIVITY; FAMILIAL HYPERLIPEMIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0033913206     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.7.1789     Document Type: Article

References (55)

1. Reaven G. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 1992;41:16-19.
2. Laakso M, Rönnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care. 1988;11:449-463.
3. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin -dependent diabetes mellitus. N Engl J Med. 1989;321: 337-343.
4. Kahn C. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43:1066-1084.
5. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest. 1998;101:86-96.
6. Aitman T, Godsland I, Farren B, Crook D, Wong J, Scott J. Defects in insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1997;17: 748-754.
7. Bredie S, Cees J, Smits P, Stalenhoef A. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their non-affected relatives. Arterioscler Thromb Vasc Biol. 1997;17:1465-1471.
8. Ascaso J, Lorente R, Merchante A, Real J, Priego A, Carmena R. Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:484-487.
9. Karjalainen L, Pihlajamäki J, Karhapää P, Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemias? Arterioscler Thromb Vasc Biol. 1998;18:1548-1553.
10. Moller D, Bjorbek C, Vidal-Puig A. Candidate genes for insulin resistance. Diabetes Care. 1996;19:396-400.
11. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 1995;6:291-305.
12. Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998; 9:211-219.
13. Hegele R, Little J, Vezina C, Maguire G, Tu L, Wolever T, Jenkins D, Connelly P. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 1993;13: 720-728.
14. Knudsen P, Antikainen M, Ehnholm S, Uusi-Oukari M, Tenkanen H, Lahdenperä S, Kahri J, Tilly-Kiesi M, Bensadoun A, Taskinen M, et al. A compound heterozygote for hepatic lipase gene mutations Leu334→Phe and Thr383→Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res. 1996;37:825-834.
15. Goldstein J, Schrott H, Hazzard W, Bierman E, Motulsky A. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
16. Nikkilä E, Aro A. A family study of lipids and lipoproteins in coronary heart disease. Lancet. 1973;1:954-958.
17. Guerra R, Wang J, Grundy S, Cohen J. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 1997;94:4532-4537.
18. Vega G, Clark L, Tang A, Marcovina S, Grundy S, Cohen J. Hepatic lipase activity is lower in African American men than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res. 1998;39:228-232.
19. Tahvanainen E, Syvänne M, Frick M, Murtomäki-Repo S, Antikainen M, Kesäniemi Y, Kauma H, Pasternak A, Taskinen M, Ehnholm C. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene: the LOCAT Study Investigators. J Clin Invest. 1998;101:956-960.
20. Jansen H, Chu G, Ehnholm C, Dallongeville J, Nicaud V, Talmud P. The T allele of the hepatic lipase promoter variant C-480T is associated with increased fasting lipids and HDL and increased preprandial and postprandial LpCIII:B: European Atherosclerosis Research Study (EARS) II. Arterioscler Thromb Vasc Biol. 1999;19:303-308.
21. Jansen H, Verhoeven A, Weeks L, Kastelein J, Halley D, van den Ouweland A, Jukema J, Seidell J, Birkenhager J. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol. 1997;17:2837-2842.
22. 2 cholesterol. Arterioscler Thromb Vasc Biol. 1998;18:1723-1729.
23. De la Chapelle A. Disease gene mapping in isolated human populations the example of Finland. J Med Genet. 1993;30:857-865.
24. Kittles R, Perola M, Peltonen L, Bergen A, Aragon R, Virkkunen M, Linnoila M, Goldman D, Long J. Dual origins of Finns revealed by Y chromosome haplotype variation. Am J Hum Genet. 1998;62:1171-1179.
25. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985.
26. Voutilainen E. Serum Lipids and Lipoproteins in Male Survivors of Acute Myocardial Infarction and Their First-Degree Relatives: A Case-Control Study. Kuopio, Finland: Kuopio University Publications; 1992.
27. Koivisto U, Hämäläinen L, Taskinen M, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J Lipid Res. 1993;34:269-277.
28. Haffner S, Karhapää P, Mykkänen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994;43:212-219.
29. Niskanen L, Karjalainen L, Siitonen O, Uusitupa M. Metabolic evaluation of type 2 diabetes: a ten-year follow-up from the time of diagnosis. J Intern Med. 1994;236:263-270.
30. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and insulin resistance. Am J Physiol. 1979; 237:E214-E223.
31. Bergman R, Finegood D, Ader M. Assessment of insulin sensitivity in vivo. Endocrinol Rev. 1985;5:45-86.
32. Laakso M, Uusitupa M, Takala J, Majander H, Reijonen T, Penttilä I. Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. Metabolism. 1988;37:1092-1100.
33. Takala J, Keinänen O, Väisänen P, Kari A. Measurement of gas exchange in intensive care laboratory and clinical validation of a new device. Crit Care Med. 1989;17:1041-1047.
34. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism. 1988;37:287-301.
35. Penttilä I, Voutilainen E, Laitinen P, Juutilainen P. Comparison of different analytical and precipitation methods for the direct estimation of serum high density lipoprotein cholesterol. Scand J Clin Lab Invest. 1984;41:353-360.
36. Laakso M, Sarlund H, Mykkänen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis. 1990;10:223-231.
37. Hawk P, Oser B, Summerson W. Practical Physiological Chemistry. 12th ed. Toronto, Canada: Blakiston; 1947.
38. Huttunen J, Ehnholm C, Kinnunen P, Nikkilä E. An immunochemical method for selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta. 1075;63:335-347.
39. George V, Elston R. Testing the association between quantitative traits and polymorphic markers in pedigrees. Genet Epidemiol. 1987;4: 193-201.
40. Pajukanta P, Porkka K, Antikainen M, Taskinen M-R, Perola M, Murtomäki-Repo S, Ehnholm S, Nuotio I, Suurinkeroinen L, Lahdenkari A-T, et al. No evidence of linkage between familial combined hyperlipidemia and genes encoding major lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol. 1997;17:841-850.
41. Fossati P, Romon-Rousseaux M. Insulin and HDL-cholesterol metabolism. Diabetes Med. 1987;13:390-394.
42. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11: 1192-1203.
43. Knudsen P, Eriksson J, Lahdenperä S, Kahri J, Groop L, Taskinen M. Changes of lipolytic enzymes cluster with insulin resistance syndrome: Botnia Study Group. Diabetologia. 1995;38:344-350.
44. Romano G, Patti L, Innelli F, Di Marino L, Annuzzi G, lavicoli M, Coronel G, Riccardi G, Rivellese A. Insulin and sulfonylurea therapy in NIDDM patients: are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes. 1997;46:1601-1606.
45. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
46. Deeb S, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in the human peroxisome proliferates activated receptor gamma 2 is associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-287.
47. Nie L, Wang J, Clark L, Tang A, Vega G, Grundy S, Cohen J. Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res. 1998;39: 1127-1130.
48. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen C, Haring H. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 1999;48:1113-1119.
49. Tikkanen M, Nikkilä E. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J. 1987;113:562-567.
50. Zambon A, Hokanson J, Brown B, Brunzell J. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99: 1959-1964.
51. Laakso M. Dyslipidaemias, insulin resistance and atherosclerosis. Ann Med. 1992;24:505-509.
52. Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss R. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;13:1917-1921.
53. Austin M. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
54. Hadzopoulou-Cladaras M, Cardot P. Identification of a cis-acting negative DNA element which modulates human hepatic triglyceride lipase gene expression. Biochemistry. 1993;32:9657-9667.
55. Wang D, Sul H. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway: involvement of protein kinase B/Akt. J Biol Chem. 1998;273:25420-25426.